Table 1.
Demographic Data on Control and Respiratory Disease Study Subjects†
| Variables | Assay Validation Studies | Comparison Studies | Responsiveness Studies | |||||
|---|---|---|---|---|---|---|---|---|
| Asthma (n = 30) | COPD (n = 11) | Healthy Controls (n = 8) | Assessments of Sputum Supernatants vs. Filtrates (n = 43) | Assessments of Plasma (n = 20) vs. Serum (n = 20) | Mepolizumab™ (n = 13) | Allergen (n = 6) | ||
| Plasma | Serum | |||||||
| Number of Males/Females | 9/21 | 2/9 | 4/4 | 17/28 | 9/11 | 5/15 | 8/5 | 3/3 |
| Age (years) | 46.0 ± 17.2 | 68.8 ± 4.7 | 54.0 ± 14 | 55.8 ± 16.8 | 46.7 ± 14.4 | 49.0 ± 15.4 | 58.5 ± 8.9 | 34.2 ± 12.6 |
| FEV1 (L) | 2.7 ± 1.1 | 1.6 ± 0.4 | 2.5 ± 1.1 | 1.9 ± 0.9 | 3.0 ± 0.9 | 2.2 ± 0.9 | 2.0 ± 0.8 | 3.4 ± 0.4 |
| FEV1 (%) | 84.9 ± 24.0 | 65.2 ± 21.1 | 86.9 ± 10.3 | 63.5 ± 29.3 | 87.1 ± 19.3 | 75.5 ± 23.1 | 65.1 ± 18.3 | 89.3 ± 8.2 |
| FEV1/FVC (%) | 75.0 ± 12.2 | 54.7 ± 17.0 | 81.4 ± 8.8 | 65.1 ± 18.8 | 85.5 ± 10.8 | 65.8 ± 28.5 | 66.3 ± 16.4 | 79.0 ± 7.9 |
| TCC (×10−6/g)¶ | 10.3 ± 16.2 | 6.80 ± 6.4 | 6.1 ± 2.5 | 10.9 ± 17.1 | 5.6 ± 4.5 | 3.8 ± 2.1 | 6.63 ± 7.2 | 5.2 ± 5.3 |
| Viability (%) | 63.6 ± 15.6 | 52.1 ± 20.6 | 78.0 ± 12.0 | 67.2 ± 18.1 | 63.4 ± 17.7 | 56.2 ± 18.7 | 57.0 ± 18.7 | 49.7 ± 20.0 |
| Neutrophil‡ (%) | 49.3 ± 31.3 | 53.3 ± 25.4 | 55.8 ± 19.9 | 59.7 ± 29.6 | 48.6 ± 24.6 | 44.4 ± 27.6 | 50.6 ± 26.3 | 30.3 ± 17.7 |
| Eosinophil‡ (%) | 3.6 [6.4] | 8.1 [5.1] | 0.2 [0.1] | 4.7 [10.5] | 3.8 [5.8] | 16.0 [24.2] | 11.6 [17.7] | 11.7 [12.6] |
†
Data are represented as mean ± SD, except for the % eosinophil which is expressed as median [IQR]
¶
TCC - total cell count (×10−6/gram of sputum)
‡
% of total sputum leukocytes